Sentences with phrase «lymphoblastic leukemia in»

After all, the cancer survivor and team leader of Lavell & Associates, Better Homes and Gardens Desert Properties in Henderson, Nev., was «dragged to the camp» as a 14 - year - old who had been diagnosed with acute lymphoblastic leukemia in 1997.

The EPHX1 rs1051740 Polymorphism Is Associated with Childhood Acute Lymphoblastic Leukemia in a Korean Population

UNC569, a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

However, genetic mutations in a gene called mixed lineage leukemia, or MLL, lead to an aggressive subtype of B - ALL known as MLL - rearranged, which is the most common type of acute lymphoblastic leukemia in infants.

SPENCER SARTIN wasdiagnosed with acute lymphoblastic leukemia in October 2004.

JP Gibson, a 5 - year - old who was diagnosed with acute lymphoblastic leukemia in 2012, was signed to a one - day contract by the Utah Jazz.

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

Not exact matches

JCAR015 is a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

He remains a leader in supportive care and research in pediatric oncology, with a special focus on neuroblastoma, non-Hodgkin lymphoma, Ewing Sarcoma, acute lymphoblastic leukemia and brain tumors.

According to new information in cancer research, there could be a new correlation between C - section delivery and Lymphoblastic Leukemia.

Acute lymphoblastic leukemia is most frequent in children, adolescents and young adults, and it has a five - year survival rate of over 90 %.

An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

«Protein isolated from baker's yeast shows potential against leukemia cells: Researchers performed in vitro trials to test the effect of L - asparaginase on acute lymphoblastic leukemia cells and published the results in Scientific Reports.»

In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

The most common cancer in children is called B - acute lymphoblastic leukemia, also known as B - ALL.

The gene (E2A) that codes for proteins with the properties of immunoglobulin enhancer binding factors E12 / E47 was mapped to chromosome region 19p13.2 - p 13.3, a site associated with nonrandom translocations in acute lymphoblastic leukemias.

Two different approaches are driving the buzz, and one of them got a big boost in August when the Food and Drug Administration approved a «living drug» to treat acute lymphoblastic leukemia (ALL) in children and young adults who've stopped responding to chemotherapy.

Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease.

The therapy has led to remission rates as high as 90 % in children and young adults with B - cell acute lymphoblastic leukemia (ALL); however, the side - effects can be extreme and difficult to manage.

A University of Colorado Cancer Center study published today in the journal Nature Genetics describes a newly - discovered, heritable genetic cause of acute lymphoblastic leukemia (ALL), namely mutation of the gene ETV6.

A patent application for a drug that could destroy the deadly childhood disease known as acute lymphoblastic leukemia — and potentially other cancers as well — has been submitted by researchers at Sandia National Laboratories, the University of Maryland and the MD Anderson Cancer Center in Houston.

«Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied.»

ST. LOUIS, MISSOURI — A few months before completing medical school in 2003, Lukas Wartman was diagnosed with acute lymphoblastic leukemia (ALL), a blood cancer that's particularly lethal when it strikes adults.

«Role of RNA binding protein in driving cancer, leukemia study reveals: Abnormally expressed in cancer cells, the protein was found to promote the proliferation of B cells in B - cell acute lymphoblastic leukemia.»

The new study, published March 14 in the Journal of Clinical Investigation, focused on a particularly aggressive form of B - cell acute lymphoblastic leukemia (B - ALL), the most prevalent type of leukemia in children and young adults.

Noelle Frey, MD, an assistant professor of Hematology - Oncology, will present results in 27 adult patients with acute lymphoblastic leukemia (ALL), identifying an optimal dose and infusion regimen that should improve treatment response while reducing potential for side effects.

His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.

A few months before completing medical school in 2003, Lukas Wartman was diagnosed with acute lymphoblastic leukemia, a blood cancer that's particularly lethal when it strikes adults.

The FDA approves Blincyto (blinatumomab) for use in the treatment of B cell acute lymphoblastic leukemia (ALL).

A Phase III Randomized Trial for Newly Diagnosed High Risk B - precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND # 73789, NSC # 606869) in the Very High Risk Stratum

[3]-RRB- However, the presence of the Philadelphia (Ph) chromosome is not sufficiently specific to diagnose CML, since it is also found in acute lymphoblastic leukemia [4](aka ALL, 25 — 30 % of adult cases and 2 — 10 % of pediatric cases) and occasionally in acute myelogenous leukemia (AML).

The FDA granted approval to a new, first - in - class immunotherapy — tisagenlecleucel (Kymriah, Novartis)-- for the treatment patients up to 25 years old with B cell acute lymphoblastic leukemia (B - ALL) that is refractory or has relapsed after at least two previous treatments.

It's the most common cancer - causing gene in T - cell acute lymphoblastic leukemia.

In 2014, the FDA approved Amgen's BLINCYTO ® (blinatumumab), the first BiTE ® therapy to receive FDA approval, for the treatment of Philadelphia chromosome - negative relapsed or refractory B - cell precursor acute lymphoblastic leukemia, a rare and rapidly progressing cancer of the blood and bone marrow.

Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21

Lewis B. Silverman, MD Clinical Director, Hematologic Malignancy Center Dr. Silverman's major research focus is in childhood acute lymphoblastic leukemia (ALL).

Risk - Stratified Randomized Phase III Testing of Blinatumomab (IND # 117467, NSC # 765986) in First Relapse of Childhood B - Lymphoblastic Leukemia (B - ALL)

Gut Microbiome Composition Predicts Infection Risk during Chemotherapy in Children with Acute Lymphoblastic Leukemia — Hana Hakim — Clinical Infectious Diseases

CAR T - cell treatment, on the other hand, is being widely tested in children and has shown impressive effectiveness against the most common childhood leukemia, called acute lymphoblastic leukemia.

The use of minimal residual disease (MRD) provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) than did morphology, according to the results of a study published recently in the Journal of Clinical Oncology.

Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T - cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.

Study finds age, ancestry and genetics can influence the risk of pancreatitis, a serious chemo side effect in acute lymphoblastic leukemia patients.

Common acute lymphoblastic leukemia usually develops in children between the ages of two and five years, and accounts for approximately 80 percent of the cases of childhood leukemia.

Myosin - IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia.

An international group of researchers led by Prof. Jan Cools of the VIB - KU Leuven Center for Cancer Biology have made a breakthrough in understanding the development of acute lymphoblastic leukemia, an aggressive cancer of the blood.

Endari, the first new treatment for patients with sickle cell disease in almost 20 years, Genentech's Hemlibra, the first - ever non-blood product to treat patients with hemophilia A with inhibitors, Actemra, the first treatment for adults diagnosed with giant cell arteritis, BioMarin's Brineura, the first treatment for a form of Batten disease, Benznidazole, the first U.S. treatment for Chagas disease, Novartis» Kymriah to treat certain children and young adults with B - cell acute lymphoblastic leukemia, which is also the first gene therapy to become available in the United States, are some of the drugs that received the FDA's stamp of approval in 2017.

The changes included reductions in the use and dose of radiation therapy and chemotherapy drugs called anthracyclines for treatment of acute lymphoblastic leukemia (ALL), Hodgkin lymphoma and Wilms tumor, a cancer of the kidneys.

Integrating genetic risk factors with minimal residual disease (MRD) improves the accuracy of risk stratification for children with acute lymphoblastic leukemia (ALL), according to a population - based cohort study published in the Journal of Clinical Oncology.